Carregant...
Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
PURPOSE: To review published evidence for a treatment interval extension to ≥12-weeks in neovascular macular degeneration treated with intravitreal Aflibercept. METHODS: A systematic search was performed in the NCBI/PubMed database to identify pro- and retrospective studies retrieved by the key term...
Guardat en:
| Publicat a: | Clin Ophthalmol |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6650619/ https://ncbi.nlm.nih.gov/pubmed/31409968 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S185756 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|